Cholestech's Consumer Play
Executive Summary
Cholestech Inc. a maker of point-of-care diagnostic tests for cholesterol levels, is revamping its strategy to focus more on the consumer. It is buying Health Net, a small operator of alternative site testing services, such as those offered in corporations, shopping malls and at special events, to help augment relationships with pharmaceutical companies and to expand its Internet presence. Calling its new services WellCheck, it aims to attract pharmaceutical companies to sponsor consumer testing programs. Health Net has about $3 million in revenues, much of it coming from Warner-Lambert's Parke Davis subsidiary and Pfizer Inc., which have a co-marketing agreement to sell Lipitor, the best-selling cholesterol-lowering drug. The drug companies are supporting Health Net's testing efforts in the hopes of increasing awareness of their drug and perhaps more importantly improving compliance. Cholestech is also setting up its own Internet portal via WellCheck. Inc., which will be sponsored by pharmaceutical companies and which will allow consumers to maintain their health records on line.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.